14,640 results match your criteria: "European urology[Journal]"
How To Write a Response to Reviewers.
Eur Urol
January 2025
Division of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Peer review and comments from reviewers are part of the submission process for scientific papers. We provide tips on how best to respond to reviewers, and point out the most common mistakes that authors make. The ultimate goal is to work with reviewers and editors to improve the quality of a paper so that it is accepted for publication.
View Article and Find Full Text PDFHow Sound Are High-intensity Focused Ultrasound Data?
Eur Urol
January 2025
Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Electronic address:
Reply to Jonas Hugosson. Population-based Screening for Prostate Cancer: Is It Time? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.003.
Eur Urol
January 2025
Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Testicular Germ Cell Tumor Etiology: Still a Black Box?
Eur Urol
December 2024
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Reply to Aravindh Rathinam, Jonathan Katz, Robert Marcovich, and Hemendra N. Shah's Letter to the Editor re: Michael Baboudjian, Hashim Hashim, Nikita Bhatt, et al. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2024;86:213-20.
Eur Urol
December 2024
Department of Urology, CHU Hôpitaux de Rouen-Hôpital Charles Nicolle, Rouen, France.
The Financial Burden of Localized and Metastatic Bladder Cancer.
Eur Urol
December 2024
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Bladder cancer (BCa) presents a significant financial challenge for both healthcare systems and patients, necessitating an understanding of its economic impacts for better resource management and treatment effectiveness.
- A systematic review was performed following PRISMA guidelines to assess the financial implications of BCa, including various costs, cost effectiveness, and the phenomenon of financial toxicity (FT) across multiple studies.
- High-risk non-muscle-invasive BCa can lead to expenses over $200,000 within five years, while metastatic BCa presents the most financial strain, with treatment costs ranging wildly and disproportionately affecting younger, less-educated, and minority groups.
Re: Michael Baboudjian, Hashim Hashim, Nikita Bhatt, et al. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2024;86:213-20.
Eur Urol
December 2024
Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA. Electronic address:
Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate?
Eur Urol
December 2024
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey. Electronic address:
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Eur Urol
December 2024
Department of Oncology, University of Debrecen, Debrecen, Hungary.
Article Synopsis
- - Patients with advanced/metastatic urothelial carcinoma who previously responded to or maintained stable disease with pembrolizumab immunotherapy may benefit from retreatment after disease progression, based on a post hoc analysis involving 49 patients from earlier clinical trials.
- - The study found that 41% of these patients achieved an objective response following retreatment, with a notable percentage having had a complete response during the initial treatment, and the median duration of the response was around 14 months.
- - Additionally, the retreatment led to manageable adverse effects, with only 45% experiencing treatment-related events, indicating that pembrolizumab retreatment is a viable and relatively safe option for select patients.
Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life.
Eur Urol
December 2024
Department of Urology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address:
Background And Objective: Treatment burden refers to the overall impact of medical treatments on a patient's well-being and daily life. Our objective is to evaluate the impact of treatment burden on quality of life (QoL) in patients with genitourinary (GU) malignancies, highlighting the importance of patient-reported outcomes (PROs) in clinical trials to inform treatment decisions and improve patient care.
Methods: We conducted a narrative review of clinical trials focused on GU malignancy (prostate, bladder, and kidney) between January 2000 and June 2024, analyzing related PROs and findings regarding treatment burden.
Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.
Eur Urol
December 2024
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Trials have shown that prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) is more accurate than conventional imaging for staging of nodal status in prostate cancer. We discuss the advantages of PSMA PET/CT over current options for nodal staging and highlight the issues that need to be resolved for implementation of this modality in routine practice.
View Article and Find Full Text PDFOptimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
Eur Urol
December 2024
Department of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address:
Optimal treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) are evolving with novel multimodal approaches. For well-selected patients, early local radiotherapy can play a pivotal role in high-volume mHSPC. Radiotherapy controls local disease, reduces symptoms, and may potentially delay castration resistance, warranting its consideration alongside systemic therapies in high-volume mHSPC.
View Article and Find Full Text PDFThe Discrepancy Between Patient-reported Outcomes, Adverse Events, and Radiographic Progression-free Survival in MAGNITUDE and Other Recent Trials.
Eur Urol
December 2024
Department of Medicine, Division of Oncology, University of Washington (retired), Seattle, WA, USA. Electronic address:
Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Choice or a Fine Balance?
Eur Urol
December 2024
Division of Surgery and Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK. Electronic address:
Clinical Implementation of Minimal Residual Disease Testing in Genitourinary Cancers: Bridging Promise and Practice.
Eur Urol
December 2024
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies.
Eur Urol
January 2025
The Christie and Salford Royal Hospitals, Manchester, UK. Electronic address:
Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy-A New Standard for Guidelines on Prostate Cancer Detection?
Eur Urol
December 2024
Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
Eur Urol
December 2024
Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.
Background And Objective: Our aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.
Methods: We analyzed age-standardized PC incidence and mortality rates by country and region from the 2022 GLOBOCAN estimates and temporal trends in incidence (50 countries/territories) and mortality (59 countries/territories) rates using data from the Cancer Incidence in Five Continents series and the World Health Organization mortality database.
Key Findings And Limitations: Estimated PC rates across regions in 2022 varied 13-fold for incidence and 9.
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.
Eur Urol
December 2024
Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Article Synopsis
- Advances in molecular diagnostics are transforming how prostate, renal, and urothelial cancers are assessed, offering more accurate detection methods for disease burden and minimal residual disease (MRD).
- A literature review from 1980-2024 highlights emerging radiographic and molecular tools aimed at improving disease quantification and monitoring through innovative technologies and biomarker-informed trials.
- New developments, like novel radiotracers and molecular detection methods (e.g., circulating tumor DNA), provide insights into disease mechanisms and have the potential to enhance clinical management, although full MRD application is still in progress.
Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
Eur Urol
December 2024
Department of Urology, CHU Toulouse, Toulouse, France.
Article Synopsis
- A French nationwide trial compared high-intensity focused ultrasound (HIFU) with radical prostatectomy (RP) for treating localized prostate cancer, focusing on salvage therapy-free survival (STFS) and other outcomes in 3328 patients from 2015 to 2019.
- HIFU showed similar STFS at 30 months compared to RP, with lower rates of urinary continence deterioration and less significant erectile function decline among HIFU patients, although some limitations like lack of randomization and age differences in groups were noted.
- The study suggests that HIFU is a viable alternative to RP for low- to intermediate-risk prostate cancer with favorable outcomes for urinary and sexual function, indicating
Re: Risk Factors for Artificial Urinary Sphincter Explantation and Erosion in Male Nonneurological Patients.
Eur Urol
November 2024
Department of Urology, Section of Pelvic and Reconstructive Urology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Can a Molecular Classifier of Upper Tract Urothelial Carcinoma Inform Clinical Decision-making and Biological Stratification?
Eur Urol
November 2024
Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR.
Eur Urol
November 2024
Department of Radiation Oncology, University of Chicago, Chicago, IL, USA.
Despite an Abundance of Active Treatment Options for Renal Cell Carcinoma, Shadows Still Obscure the Light.
Eur Urol
November 2024
Division of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy.
Re: Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial.
Eur Urol
November 2024
Division for Mental and Physical Health, National Institute of Public Health, Oslo, Norway.